Search
                    Systemic Lupus Erythematosus Clinical Trials
A listing of 45  Systemic Lupus Erythematosus  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 12 of 45
        
                There are currently 45 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Lupus Nephritis Clinical Study
            
        Recruiting
            
        The Ntrust-1 study is part of a broad effort of the global research community to develop more treatment options for people living with lupus nephritis (LN). You may be eligible to participate in this study if you:
 Are 18 to 65 years old.
 Have been diagnosed with lupus nephritis.
 Have received at least two prior therapies for lupus nephritis.
     Are 18 to 65 years old.
 Have been diagnosed with lupus nephritis.
 Have received at least two prior therapies for lupus nephritis.
                            Conditions: 
                                    
        
            
                        Lupus
                    
                                    
                        Systemic Lupus Erythematosus
                    
                                    
                        Lupus Nephritis
                    
                                    
                        Lupus Erythematosus
                    
                                    
                        Systemic
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    
                
                                    BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
                                
            
            
        Recruiting
                            
            
                This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve SLE disease activity scores.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 65 years
            Trial Updated:
                05/28/2025
            
            Locations: Nationwide Children's, Columbus, Ohio         
        
        
            Conditions: Systemic Lupus Erythematosus
        
            
        
    
                
                                    Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
                                
            
            
        Recruiting
                            
            
                Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 63 years
            Trial Updated:
                08/21/2025
            
            Locations: AZ Arthritis and Rheumatology /ID# 261848, Chandler, Arizona  +352 locations         
        
        
            Conditions: Systemic Lupus Erythematosus
        
            
        
    
                
                                    A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/18/2025
            
            Locations: Local Institution - 0237, Searcy, Arkansas  +206 locations         
        
        
            Conditions: Systemic Lupus Erythematosus
        
            
        
    
                
                                    A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/08/2025
            
            Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado  +53 locations         
        
        
            Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
        
            
        
    
                
                                    A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.             
        
        
    Gender:
                ALL
            Ages:
                16 years and above
            Trial Updated:
                08/07/2025
            
            Locations: Sl0044 50058, Avondale, Arizona  +158 locations         
        
        
            Conditions: Systemic Lupus Erythematosus
        
            
        
    
                
                                    A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/07/2025
            
            Locations: University of Alabama at Birmingham, Birmingham, Alabama  +221 locations         
        
        
            Conditions: Systemic Lupus Erythematosus
        
            
        
    
                
                                    Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
                                
            
            
        Recruiting
                            
            
                This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include:
* Study duration: 36 weeks
* Treatment duration: 24 weeks
* Visit frequency: every 2 weeks             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                08/07/2025
            
            Locations: Accel Resarch Sites- Site Number : 8400003, Birmingham, Alabama  +69 locations         
        
        
            Conditions: Systemic Lupus Erythematosus
        
            
        
    
                
                                    A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
                                
            
            
        Recruiting
                            
            
                The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with nephritis (Subprotocol B) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C).             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/06/2025
            
            Locations: HonorHealth Research and Innovation Institute, Scottsdale, Arizona  +38 locations         
        
        
            Conditions: Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
        
            
        
    
                
                                    UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to evaluate the safety and effectiveness of UC-MSCs in adults with systemic lupus erythematosus (SLE).
The main questions this study aims to answer are:
1. Can UC-MSCs improve kidney function and reduce SLE disease activity?
2. Are UC-MSCs safe and well-tolerated in this patient population?
Participants in this study will:
* Receive UC-MSCs in a single dose in addition to standard of care treatment.
* Provide blood and urine samples for laboratory assessmen...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/03/2025
            
            Locations: Medical University of South Carolina, Charleston, South Carolina         
        
        
            Conditions: SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
        
            
        
    
                
                                    Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
                                
            
            
        Recruiting
                            
            
                PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement.             
        
        
    Gender:
                FEMALE
            Ages:
                All
            Trial Updated:
                07/29/2025
            
            Locations: Research Site, Las Vegas, Nevada         
        
        
            Conditions: Systemic Lupus Erythematosus
        
            
        
    
                
                                    Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).             
        
        
    Gender:
                ALL
            Ages:
                Between 12 years and 100 years
            Trial Updated:
                07/29/2025
            
            Locations: Pinnacle Research Group Llc, Anniston, Alabama  +79 locations         
        
        
            Conditions: Systemic Lupus Erythematosus
        
            
        
    
                
                                    A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
                                
            
            
        Recruiting
                            
            
                This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable initial SLE therapy.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/28/2025
            
            Locations: GSK Investigational Site, Anniston, Alabama  +99 locations         
        
        
            Conditions: Systemic Lupus Erythematosus
        
            
        
    1 - 12 of 45
            